2026-10-14T14:18:32Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33995469 2026-10-01T14:54:37Z category_67901 portal_1154 item_type_7 month_year_10_2026

Congress Presentation: IMS 2026 Patient Global Impression of Severity and Change with elinzanetant: results from Phase III OASIS-1 and -2 trials JoAnn V. Pinkerton (21671538) Rossella E. Nappi (2744353) Marla Shapiro (4616977) Celine Bouchard (20451130) Senka Djordjevic (21842853) Ioanna Gkioni (21842866) Andrew Trigg (3968021) James A. Simon (13763258) Menopause Elinzanetant OASIS-1 OASIS-2 Menopause <p dir="ltr">In this analysis from pooled OASIS-1 and -2 data, a greater proportion of postmenopausal women with VMS reported reductions in VMS frequency and severity and improvements in patient-perceived sleep disturbance with elinzanetant compared with those on placebo, as measured by the Patient Global Impression of Severity (PGI-S) and Change (PGI-C).</p> 2026-10-01T14:54:37Z Text Presentation 10.71943/bayer.figshare.33995469.v1 https://figshare.com/articles/presentation/Congress_Presentation_IMS_2026_Patient_Global_Impression_of_Severity_and_Change_with_elinzanetant_results_from_Phase_III_OASIS-1_and_-2_trials/33995469 CC BY-ND